Simultaneous targeting of mitochondria and monocytes enhances neuroprotection against ischemia-reperfusion injury

Area of Science:

• Neuroscience
• Cardiovascular Research
• Pharmacology

Background:

• Ischemia-reperfusion injury significantly hinders effective reperfusion therapy for ischemic stroke.
• Mitochondrial permeability transition pore (mPTP) opening, mediated by Cyclophilin D (CypD), and monocyte-driven inflammation are key contributors to this injury.
• Currently, no specific medical therapies exist to counteract these mechanisms.

Purpose of the Study:

• To investigate the hypothesis that simultaneously targeting mPTP opening and inflammation provides substantial neuroprotection post-cerebral ischemia-reperfusion.
• To evaluate the efficacy of a combined therapeutic strategy involving CypD and C-C chemokine receptor 2 (CCR2) pathways.

Main Methods:

• Generation and utilization of CypD knockout, CCR2 knockout, and CypD/CCR2 double knockout mice.
• Induction of transient cerebral ischemia via middle cerebral artery occlusion for 60 minutes.
• Administration of cyclosporine A (CsA)-loaded polymeric nanoparticles (CsA-NPs) and pitavastatin (Pitava-NPs) targeting mPTP and inflammation, respectively.

Main Results:

• CypD/CCR2 double knockout mice exhibited significantly reduced neurological deficits compared to wild-type and single knockout groups.
• Simultaneous administration of CsA-NPs and Pitava-NPs markedly decreased infarct size and neurological deficits.
• The combined nanoparticle treatment demonstrated superior efficacy over single-agent nanoparticle treatments and control nanoparticles.

Conclusions:

• Simultaneous targeting of mPTP opening and monocyte-mediated inflammation represents a promising novel therapeutic strategy for ischemic stroke.
• This dual-action approach holds potential for improving neurological outcomes in patients undergoing reperfusion therapy.